Delilah Alvarado Obesity drug startup Metsera said Tuesday it has signed a deal with manufacturing firm Amneal ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...

MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and ...

Breast cancer remains the most common cancer among women in Canada, but early detection can save lives. PocketHealth is ...

Obesity startup Metsera is getting a new manufacturing partner and a new CEO. On Tuesday, the well-funded startup announced ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Today, a brief rundown of news from Biogen, as well as updates from Dyne Therapeutics, Denali Therapeutics and Novo Nordisk that you may have missed.

Following its $2.7 billion acquisition of Carmot Therapeutics, Roche (ROG: SIX) is intensifying its focus on obesity treatments, details of which have been set out at an investor event. The Swiss ...

BOSTON--(BUSINESS WIRE)--#AI--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present early safety and efficacy data for ...